RegentAtlantic Capital’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $985K | Sell |
12,956
-2,894
| -18% | -$240K | 0.03% | 309 |
|
|
2022
Q2 | $1.34M | Sell |
15,850
-1,275
| -7% | -$112K | 0.04% | 261 |
|
|
2022
Q1 | $1.5M | Sell |
17,125
-1,434
| -8% | -$124K | 0.04% | 259 |
|
|
2021
Q4 | $1.62M | Sell |
18,559
-580
| -3% | -$48.2K | 0.05% | 248 |
|
|
2021
Q3 | $1.56M | Sell |
19,139
-1,510
| -7% | -$136K | 0.05% | 239 |
|
|
2021
Q2 | $1.88M | Sell |
20,649
-2,458
| -11% | -$219K | 0.06% | 216 |
|
|
2021
Q1 | $1.98M | Buy |
23,107
+17
| +0.1% | +$1.53K | 0.07% | 190 |
|
|
2020
Q4 | $2.18M | Sell |
23,090
-4,592
| -17% | -$401K | 0.09% | 161 |
|
|
2020
Q3 | $2.41M | Sell |
27,682
-10,498
| -27% | -$909K | 0.11% | 136 |
|
|
2020
Q2 | $3.33M | Sell |
38,180
-2,737
| -7% | -$236K | 0.19% | 106 |
|
|
2020
Q1 | $3.37M | Sell |
40,917
-4,218
| -9% | -$376K | 0.26% | 90 |
|
|
2019
Q4 | $4.27M | Buy |
45,135
+1,021
| +2% | +$91.6K | 0.26% | 100 |
|
|
2019
Q3 | $3.83M | Sell |
44,114
-162
| -0.4% | -$14.5K | 0.25% | 105 |
|
|
2019
Q2 | $4.04M | Buy |
44,276
+15,031
| +51% | +$1.27M | 0.27% | 89 |
|
|
2019
Q1 | $2.52M | Buy |
29,245
+2,194
| +8% | +$176K | 0.18% | 131 |
|
|
2018
Q4 | $2.08M | Sell |
27,051
-76
| -0.3% | -$5.92K | 0.18% | 140 |
|
|
2018
Q3 | $2.09M | Buy |
27,127
+1,422
| +6% | +$105K | 0.16% | 154 |
|
|
2018
Q2 | $1.74M | Sell |
25,705
-1,509
| -6% | -$104K | 0.15% | 155 |
|
|
2018
Q1 | $1.97M | Sell |
27,214
-1,136
| -4% | -$86.5K | 0.16% | 144 |
|
|
2017
Q4 | $2.13M | Sell |
28,350
-136
| -0.5% | -$10.3K | 0.17% | 139 |
|
|
2017
Q3 | $2.19M | Sell |
28,486
-213
| -0.7% | -$16.1K | 0.19% | 134 |
|
|
2017
Q2 | $2.15M | Sell |
28,699
-2,955
| -9% | -$209K | 0.2% | 133 |
|
|
2017
Q1 | $2.11M | Sell |
31,654
-3,058
| -9% | -$204K | 0.2% | 134 |
|
|
2016
Q4 | $2.27M | Sell |
34,712
-3,027
| -8% | -$196K | 0.22% | 121 |
|
|
2016
Q3 | $2.67M | Sell |
37,739
-827
| -2% | -$60.3K | 0.28% | 97 |
|
|
2016
Q2 | $2.85M | Sell |
38,566
-4,262
| -10% | -$294K | 0.28% | 92 |
|
|
2016
Q1 | $2.78M | Buy |
42,828
+161
| +0.4% | +$11K | 0.31% | 81 |
|
|
2015
Q4 | $3.29M | Sell |
42,667
-3,696
| -8% | -$294K | 0.35% | 75 |
|
|
2015
Q3 | $3.82M | Sell |
46,363
-3,202
| -6% | -$285K | 0.37% | 71 |
|
|
2015
Q2 | $4.37M | Sell |
49,565
-3,318
| -6% | -$304K | 0.39% | 71 |
|
|
2015
Q1 | $4.67M | Sell |
52,883
-2,673
| -5% | -$237K | 0.41% | 67 |
|
|
2014
Q4 | $4.61M | Sell |
55,556
-945
| -2% | -$78.3K | 0.39% | 67 |
|
|
2014
Q3 | $4.77M | Sell |
56,501
-1,316
| -2% | -$106K | 0.45% | 57 |
|
|
2014
Q2 | $4.69M | Sell |
57,817
-1,046
| -2% | -$82.3K | 0.44% | 61 |
|
|
2014
Q1 | $4.48M | Sell |
58,863
-5,786
| -9% | -$422K | 0.44% | 66 |
|
|
2013
Q4 | $4.66M | Buy |
64,649
+173
| +0.3% | +$12K | 0.45% | 59 |
|
|
2013
Q3 | $4.43M | Buy |
64,476
+1,181
| +2% | +$78.1K | 0.48% | 52 |
|
|
2013
Q2 | $4.01M | Buy |
+63,295
| New | +$4.12M | 0.48% | 55 |
|
Other funds holding NVS
RegentAtlantic Capital's NVS Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Novartis (NVS) stake by 18% in Q3 2022, selling an estimated $240K and leaving 12,956 shares worth $985K. The position accounts for 0.03% of the portfolio, ranked #309.
RegentAtlantic Capital first reported a position in NVS in Q2 2013 and has held it in 38 quarters since. The position peaked at $4.77M in Q3 2014. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.
- RegentAtlantic Capital held 12,956 shares of Novartis worth $985K as of Q3 2022.
- RegentAtlantic Capital sold 2,894 Novartis shares in Q3 2022, an estimated $240K.
- Novartis made up 0.03% of RegentAtlantic Capital's portfolio in Q3 2022, its #309 holding.
- RegentAtlantic Capital first reported a position in Novartis in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Novartis position peaked at $4.77M in Q3 2014.
- 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.